-+ 0.00%
-+ 0.00%
-+ 0.00%

Sinopharm Hyundai announced that some of the company's subsidiaries participated in the 12th batch of centralized procurement of national drugs. Pentamethaquil hydrochloride injections, ceftazidime avibactan sodium for injection, diclofenac sodium sustained-release tablets, vitamin B6 injections, and bumetanib injections will be selected. Among them, the total sales of the three products, including diclofenac sodium extended-release tablets, totaled 348 million yuan in 2025, accounting for about 3.72% of the company's revenue in 2025. The procurement period starts on the date of execution of the selected results and ends on December 31, 2029.

Zhitongcaijing·08/03/2026 08:49:08
Listen to the news
Sinopharm Hyundai announced that some of the company's subsidiaries participated in the 12th batch of centralized procurement of national drugs. Pentamethaquil hydrochloride injections, ceftazidime avibactan sodium for injection, diclofenac sodium sustained-release tablets, vitamin B6 injections, and bumetanib injections will be selected. Among them, the total sales of the three products, including diclofenac sodium extended-release tablets, totaled 348 million yuan in 2025, accounting for about 3.72% of the company's revenue in 2025. The procurement period starts on the date of execution of the selected results and ends on December 31, 2029.